Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13287388 | 0.92 | MAPK1 (0.37) | RAB9ANPC1TP53ALDH1A1HPGD | |
| SCHEMBL13287382 | 0.89 | RAB9A (0.37) | RAB9ANPC1TP53GPR139ALDH1A1 | |
| SCHEMBL13287389 | 0.88 | ADORA1 (0.36) | RAB9ANPC1TP53GPR139ALDH1A1 | |
| SCHEMBL14038883 | 0.86 | GPR139 (0.34) | RAB9ANPC1TP53GPR139ALDH1A1 | |
| SCHEMBL13287390 | 0.86 | ADORA1 (0.34) | RAB9ANPC1TP53GPR139ALDH1A1 | |
| SCHEMBL13287367 | 0.84 | NPC1 (0.37) | RAB9ANPC1ALDH1A1HPGDLMNA | |
| SCHEMBL13287357 | 0.82 | FFAR2 (0.30) | FFAR2 | |
| SCHEMBL13287397 | 0.82 | NPC1 (0.36) | RAB9ANPC1GPR139ALDH1A1LMNA | |
| SCHEMBL13287337 | 0.81 | MAPK1 (0.36) | RAB9ANPC1TP53ALDH1A1HPGD | |
| SCHEMBL13287376 | 0.80 | CSNK2A2 (0.33) | TP53ALDH1A1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | RAB9A 2769/4885NPC1 744/4885TP53 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.